The Meals and Drug Administration (FDA) has granted 510(ok) clearance for BrightHeart’s synthetic intelligence (AI)-enabled software program, which can bolster ultrasound detection of congenital coronary heart defects (CHDs) which have been estimated to happen in certainly one of each 100 newborns.
Using AI algorithms that have been developed on over 90,000 ultrasound exams, BrightHeart’s AI software program offers automated video stream evaluation and detailed evaluation of fetal coronary heart morphology, which detects or guidelines out findings suggestive of CHDs, in keeping with BrightHeart.
Providing detailed evaluation of fetal coronary heart morphology and automatic video stream evaluation, the newly FDA-cleared AI software program from BrightHeart might improve ultrasound detection of congenital coronary heart defects. (Picture courtesy of BrighHeart.)
The corporate says the software program additionally gives AI evaluation as to the completeness of fetal coronary heart ultrasound exams and facilitates easy integration into current ultrasound workflows.
“Fetal coronary heart assessments are among the many most technically demanding points of prenatal ultrasound,” stated Cécile Dupont, the CEO of BrightHeart. “Our AI-powered resolution not solely assists clinicians in detecting indicators of potential abnormalities earlier but additionally enhances their confidence in confirming regular findings, which is equally crucial for the peace of thoughts of expectant households.”
